Philip J. Johnson

Philip J. Johnson's AcademicInfluence.com Rankings

Philip J. Johnson

Engineering

#6856

World Rank

#8205

Historical Rank

Cybernetics

#139

World Rank

#145

Historical Rank

Biomedical Engineering

#641

World Rank

#651

Historical Rank

Electrical Engineering

#2086

World Rank

#2191

Historical Rank

engineering Degrees

Download Badge

Engineering

Philip J. Johnson's Degrees

PhD Biomedical Engineering Stanford University
Masters Electrical Engineering Stanford University
Bachelors Electrical Engineering University of California, Berkeley

Why Is Philip J. Johnson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Philip J. Johnson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. (1998) (1642)
Meeting report: International autoimmune hepatitis group (1993) (1025)
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. (1999) (738)
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. (1999) (523)
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. (2002) (448)
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? (1990) (417)
Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. (1999) (399)
Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. (1998) (350)
The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. (2001) (348)
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. (1995) (346)
Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. (2000) (324)
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy (2004) (303)
Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. (1995) (303)
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. (2001) (302)
Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. (1999) (291)
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. (1999) (284)
A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. (1995) (275)
Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. (1994) (231)
Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. (1996) (225)
Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma (1996) (221)
Identification of serum biomarkers for colon cancer by proteomic analysis (2006) (220)
Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity (1991) (214)
Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. (2000) (197)
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. (1999) (184)
Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. (2000) (179)
Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. (1999) (175)
Cirrhosis and the aetiology of hepatocellular carcinoma. (1987) (167)
Oestrogen receptor proteins in malignant and fetal pancreas. (1981) (165)
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. (2004) (161)
Systemic therapy for hepatocellular carcinoma. (2001) (154)
Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis. (1978) (138)
Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. (2001) (138)
INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICIN (1978) (130)
Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. (2000) (129)
A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. (1987) (129)
Internal radiation therapy for patients with primary or metastatic hepatic cancer (1998) (123)
The role of chemotherapy in the management of nasopharyngeal carcinoma (1998) (122)
Modelling prognostic factors in advanced pancreatic cancer (2008) (122)
Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. (2000) (115)
Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma (1991) (111)
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. (2006) (106)
Hepatocellular carcinoma: is current therapy really altering outcome? (2002) (105)
Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. (1999) (104)
Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. (1997) (100)
Liver tumors in wild flatfish: a histopathological, proteomic, and metabolomic study. (2005) (99)
Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. (1991) (98)
A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. (2006) (96)
Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. (1983) (95)
A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. (1998) (95)
Biology of Hepatocellular Carcinoma (2008) (94)
Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. (1980) (94)
Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. (1994) (92)
Genomic aberrations in human hepatocellular carcinomas of differing etiologies. (2000) (92)
High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. (1982) (87)
Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. (1997) (84)
A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. (1989) (84)
Non-operative arterial embolisation in primary liver tumours. (1979) (84)
Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. (1994) (78)
Structures of disease-specific serum alpha-fetoprotein isoforms (2000) (76)
Aggressive primary hepatic lymphoma in Chinese patients. Presentation, pathologic features, and outcome. (1995) (75)
Hepatic sarcomas in adults: a review of 25 cases. (1987) (75)
Proteome analysis and its impact on the discovery of serological tumor markers. (2001) (74)
Semiquantification of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. (1997) (72)
Hepatocellular carcinoma in primary biliary cirrhosis: report of four cases. (1979) (70)
Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. (1999) (69)
Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. (2004) (69)
The natural course and heterogeneity of autoimmune-type chronic active hepatitis. (1991) (68)
Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. (1999) (67)
Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. (2000) (67)
Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. (1983) (64)
Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis (2006) (63)
Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma. (1978) (63)
Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. (1987) (62)
Fatal Penicillium citrinum pneumonia with pericarditis in a patient with acute leukemia (1997) (61)
TT virus: a study of molecular epidemiology and transmission of genotypes 1, 2 and 3. (2000) (60)
Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. (1987) (58)
Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. (1978) (57)
Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour (1999) (54)
'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. (1997) (54)
Low serum testosterone concentrations in patients with carcinoma of the pancreas (1983) (53)
Identification of macrophage migration inhibitory factor and human neutrophil peptides 1–3 as potential biomarkers for gastric cancer (2009) (53)
Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. (1990) (52)
Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. (1997) (50)
Epigenetic Tumor Markers in Plasma and Serum (2001) (49)
Novel Intertypic Recombinants of Epstein-Barr Virus in the Chinese Population (2000) (49)
Injection sclerotherapy for variceal bleeding in patients with hepatocellular carcinoma: cyanoacrylate versus sodium tetradecyl sulphate. (1998) (49)
Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. (2001) (48)
A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma (1995) (48)
Hepatocellular carcinoma in the non-cirrhotic liver: a comparison with that complicating cirrhosis. (1984) (47)
Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. (1992) (47)
Relationship of p16 methylation status and serum alpha-fetoprotein concentration in hepatocellular carcinoma patients. (2000) (46)
Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma (2013) (46)
Terminology of chronic hepatitis (1995) (45)
Infectious mononucleosis presenting as acute cerebellar syndrome. (1973) (44)
Hepatocellular carcinoma during pregnancy and its comparison with other pregnancy‐associated malignancies (1995) (44)
Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. (2000) (43)
What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? (2001) (43)
Quantitative comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring. (2000) (42)
Vitamin B12 binding protein as a tumour marker for hepatocellular carcinoma. (1978) (42)
Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma. (1981) (41)
Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. (2001) (40)
Arteriovenous shunts in patients with hepatic tumors. (1997) (40)
Sex hormones and the liver. (1984) (39)
Chromosomal translocations are common in natural killer-cell lymphoma/leukemia as shown by spectral karyotyping. (2000) (37)
Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. (1994) (37)
Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model (2014) (35)
Obstructive jaundice secondary to hepatocellular carcinoma. (1995) (35)
HLA-A11-Restricted Epitope Polymorphism among Epstein-Barr Virus Strains in the Highly HLA-A11-Positive Chinese Population: Incidence and Immunogenicity of Variant Epitope Sequences (2003) (35)
Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: an analysis of 204 patients. (1987) (34)
Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. (1985) (34)
Lack of expression for the suppressor PML in human small cell lung carcinoma. (2000) (33)
Afterloading radiotherapy for local persistence of nasopharyngeal carcinoma. (1994) (33)
Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. (1998) (32)
Hepatocellular carcinoma in primary biliary cirrhosis: detection by alpha-fetoprotein estimation. (1984) (31)
Hepatitis B virus related hepatocellular carcinoma in the non-cirrhotic liver. (1991) (30)
Detection of alphafetoprotein-expressing cells in the blood of patients with hepatoma and hepatitis. (1998) (29)
Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. (1991) (29)
HLA class II alleles in Chinese patients with hepatocellular carcinoma. (2001) (29)
Preclinical and post-treatment changes in the HCC-associated serum proteome (2006) (28)
Consistent chromosome 10 rearrangements in four newly established human hepatocellular carcinoma cell lines (2002) (26)
Systemic chemotherapy of liver tumors. (2000) (25)
Role of the Standard ‘Liver Function Tests’ in Current Clinical Practice (1989) (25)
Early tumour response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma. (1996) (25)
The epidemiology of hepatocellular carcinoma. (1996) (25)
Vitamin B6 concentrations in patients with chronic liver disease and hepatocellular carcinoma. (1986) (24)
Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinoma--the possibility of radiation carcinogenesis. (1999) (24)
Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma. (2003) (24)
Detection of chromosome over- and underrepresentations in hyperdiploid acute lymphoblastic leukemia by comparative genomic hybridization. (1998) (22)
Growth factors, endocrine aspects and hormonal treatment in hepatocellular carcinoma—an overview (1990) (22)
Hepatocellular carcinoma and the art of prognostication. (2000) (21)
Ultrasound determination of liver size and assessment of patients with malignant liver disease. (2008) (21)
Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. (2001) (21)
Controversies in the management of locoregionally advanced nasopharyngeal carcinoma. (1998) (21)
MRI and CT of metastatic hepatocellular carcinoma causing spinal cord compression. (1997) (21)
Nasopharyngeal carcinoma with metastatic disease to mediastinal and hilar lymph nodes: an indication for more aggressive treatment. (1996) (20)
Use of arterial devascularization and cytotoxic drugs in 30 patients with the carcinoid syndrome. (1982) (20)
The significance of keratinizing squamous cell histology in Chinese patients with nasopharyngeal carcinoma. (1998) (19)
Significance of serum bilirubin level in response of hepatocellular carcinoma to doxorubicin. (1986) (19)
Hyperthyroxinaemia in hepatocellular carcinoma: relation to thyroid binding globulin in the clinical and preclinical stages of the disease. (1988) (19)
Germ cell tumors express a specific alpha‐fetoprotein variant detectable by isoelectric focusing (1995) (19)
Patterns of early treatment failure in non-metastatic nasopharyngeal carcinoma: a study based on CT scanning. (1994) (18)
Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma--frequency of specific banding patterns at non-diagnostic serum levels. (1996) (18)
A comprehensive karyotypic analysis on a newly developed hepatocellular carcinoma cell line, HKCI-1, by spectral karyotyping and comparative genomic hybridization. (2000) (18)
Transcriptional profiling on chromosome 19p indicated frequent downregulation of ACP5 expression in hepatocellular carcinoma (2005) (17)
Lack of expression for the suppressor PML in human small cell lung carcinoma (2000) (17)
Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. (1996) (17)
Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: implication of 1q12-21. (1999) (17)
Genetic imbalances in pT2 breast cancers of southern Chinese women. (2001) (16)
Clinical course of cirrhosis in young adults and therapeutic potential of liver transplantation. (1985) (16)
Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. (1998) (15)
A retrospective study of the use of cisplatinum-5-fluorouracil neoadjuvant chemotherapy in cervical-node-positive nasopharyngeal carcinoma (NPC). (1995) (15)
Post-conviction DNA testing: the UK's first 'exoneration' case? (2004) (15)
Frequency of asymptomatic hepatitis types B and C in an inner city community and relation to possible risk factors. (1991) (14)
Aggressive primary natural killer cell lymphoma of the caecum: a case report and literature review. (1997) (13)
Quantitative correlation of cytokeratin 19 mRNA level in peripheral blood with disease stage and metastasis in breast cancer patients: potential prognostic implications. (2001) (13)
Macrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areas (2012) (13)
Chronic active hepatitis. (1991) (12)
Of woodchucks and men: the continuing story of hepatitis B and hepatocellular carcinoma. (1982) (12)
Severe hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone in a patient receiving interferon‐α for chronic myeloid leukemia (1995) (12)
Hepatitis C antibodies and hepatocellular carcinoma: new clues or a false trail? (1990) (12)
A phase III study of doxorubicin (A) versus cisplatin (P)/ interferonα-2b (I)/ doxorubicin (A)/ fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC). (2004) (11)
Liver transplantation in a 27-year-old female with familial HBsAg-positive hepatocellular carcinoma. (1978) (11)
Serum ribonuclease in the diagnosis of pancreatic carcinoma and in monitoring chemotherapy. (1982) (11)
α-fetoprotein variants in a case of pancreatoblastoma (2000) (11)
Cosmetic outcome of breast-conserving therapy in Chinese patients with early breast cancer. (1997) (10)
Hazards of interferon treatment in patients with autoimmune chronic active hepatitis. (1994) (10)
Absence of hepatitis C virus in British patients with type 1 autoimmune chronic active hepatitis--a polymerase chain reaction and serological study. (1993) (10)
Cerebrovascular event following taxol infusion. (1994) (10)
Treatment of autoimmune hepatitis. (1997) (9)
'Spontaneous' regression of advanced leiomyosarcoma of the urinary bladder. (1997) (9)
Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma (2014) (9)
Monitoring response to treatment in liver tumours. (1999) (8)
Frequency of hepatic HBV-DNA in patients with cirrhosis and hepatocellular carcinoma: relation to serum HBV markers. (1990) (8)
The clinical features and natural history of malignant liver tumours. (1987) (8)
Thromboembolic events with paclitaxel. (1996) (7)
Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma. (2002) (7)
Assessment of proliferating cell nuclear antigen in nasopharyngeal carcinoma tissue and its relation to clinical findings. (1997) (7)
Decreased rate of growth of hepatocellular carcinoma recurrence after liver transplantation in patients maintained on cyclosporine immunosuppression. (1988) (7)
Management of hepatoma using cisplatin/epinephrine gel in patients awaiting orthotopic liver transplantation. (2001) (7)
Alpha-fetoprotein variants in a case of pancreatoblastoma. (2000) (7)
Small cell variant of Ki-1 lymphoma associated with myelofibrosis and a novel constitutional chromosomal translocation t(3;4) (q13;q12). (1996) (7)
Serum alpha-foetoprotein in hepatocellular carcinoma--value in diagnosis, and prognosis. (1980) (6)
Differential hormone-binding characteristics of thyroxine-binding globulin in hepatocellular carcinoma and cirrhosis. (1989) (5)
Strong association between hyperferritinaemia and metastatic disease in nasopharyngeal carcinoma. (1996) (5)
The Laboratory Investigation of Liver Disease (1990) (5)
Clinical and therapeutic aspects of hepatocellular carcinoma. (1977) (5)
Why can't we cure primary liver cancer? (1995) (5)
Differential binding of serum glycoproteins to lectins during hepatic regeneration in hepatocellular carcinoma and fulminant hepatic failure. (1990) (5)
Extraosseous osteogenic sarcoma of the mediastinum occurring in a Chinese patient. (1995) (5)
Serum concentrations of sex hormone binding globulin in lung cancer. (1986) (4)
Proteoglycan-collagen interactions and sub-fibrillar structure in collagen fibrils : implications in the development and remodelling of connective tissues (2009) (4)
Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. (1996) (4)
Hepatocellular carcinoma in immigrants to the United Kingdom. (1986) (4)
Molecular analysis of circulating tumor cells in peripheral blood from patients with germ cell tumor: a quantitative approach. (2000) (3)
Combating hepatocellular carcinoma with an integrated approach. (1999) (3)
Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy. (1995) (3)
Proceedings: Hepatoma in chronic liver disease. (1976) (3)
Reptilase time in cirrhosis and hepatocellular carcinoma. (1977) (3)
Hepato-cellular carcinoma and hepatitis B virus markers in Europe and U.S.A. (1979) (2)
Tumour markers in the diagnosis and management of patients with hepatocellular carcinoma. (1986) (2)
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS MARKERS IN EUROPE AND U.S.A. (1979) (2)
[Sonographic diagnosis in primary cancer of the liver]. (1983) (2)
In vitro uptake of bromodeoxyuridine by human nasopharyngeal carcinoma (NPC) and its relation to clinical findings. (1996) (2)
A randomized phase II trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: Gemcitabine alone vs. gemcitabine combined with cisplatin. (2004) (2)
Complications: benign and malignant tumors of the liver (1991) (2)
Gene expression regulation for interferon-alpha in hepatocellular carcinoma. (1993) (2)
Lung cancer resection does not change characteristic serum proteomic profiles. (2006) (1)
Advances in neoplastic disease of the liver and biliary tract. (1991) (1)
Effect of cytotoxic chemotherapy on hepatitis B viral markers in patients with hepatocellular carcinoma. (1984) (1)
Germ cell tumours---local perspectives on a curable cancer. (1997) (1)
Liver transplantation in carriers of the HBsAg: role of short-term passive prophylaxis with immunoglobulin. (1992) (1)
Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer (2008) (1)
Another treatment for primary biliary cirrhosis. (1987) (1)
Altered plasma and tissue fucosyltransferase activities in hepatocellular carcinoma. (1990) (1)
Autoimmune chronic active hepatitis. (1997) (1)
Nonseminomatous germ cell tumour of testis in Hong Kong Chinese patients. (1995) (1)
Epidemiology of hepatocellular carcinoma in the West. (1992) (0)
Discovery of a tumor-specific biomarker for gastric cancer using proteomic analysis in tissue and serum. (2009) (0)
Treatment ofinoperable hepatoceliular carcinoma withintrahepatic arterial yttrium-90 microspheres: aphase IandH study (1994) (0)
Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract (2003) (0)
[Circulating tumor DNA and its application on tumor researches]. (2001) (0)
Anonymous retrospective HIV tesing in Chinese patients with non-Hodgkin's lymphoma. (1999) (0)
Gastrointestinal and hepatic immunology: Chronic active hepatitis (1994) (0)
SERO-EPIDEMIOLOGY OF BLUE TONGUE IN DOMESTIC ANIMALS OF ANDHRA PRADESH (2006) (0)
A new randomized phase II design for testing investigational drugs in hepatocellular carcinoma (HCC). (2004) (0)
Endocrine aspects and hormonal treatment of hepatocellular carcinoma: An overview (1990) (0)
Steroid receptors and antisteroidal agents in the treatment of (human) pancreatic carcinoma (1986) (0)
Correlation of Ki67, topo IIa, MRP1, p53 and p-gp with chemo-responsiveness and survival in patients with hepatocellular carcinoma (HCC). (2006) (0)
A decade of hepatology---more refinements than breakthroughs. (1997) (0)
A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma (2019) (0)
Phase II study of combination cisplatin and adriamycin in recurrent carcinoma of the nasopharynx (2002) (0)
Hapatitis B virus (HBV) reactivation in breast cancer patients undergoing cytotoxic chemotherapy-High HBV DNA viral load is an important risk factor (2003) (0)
Translocation (5;19)(q33;q13) as the sole abnormality in a case of refractory anemia with excess of blasts in transformation. (1999) (0)
Phase II Study of the Efficacy and Safety of Cisplat in-Epinephrine Injectable Gel Adminis tered to Pat ients With Unresectable (2003) (0)
8 . 1 Identification of Hepatocellular Carcinoma-associated Serum Glycoproteins by Lectin Affinity Purification and 2 D Gel Analysis (2005) (0)
P-229 Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma (2021) (0)
An intensive screening program detected high incidence of hepatocellular carcinoma (HCC) in hepatitis B virus carriers (HBVC) with abnormal alfa-fetoprotein (AFP) or abdominal ultrasongraphy (AUS). (2004) (0)
Irish endocrine society (1986) (0)
Case two. Bleomycin cutaneous toxicity. (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Philip J. Johnson?

Philip J. Johnson is affiliated with the following schools:

Philip J. Johnson's Academic­Influence.com Rankings

Philip J. Johnson's Degrees

Why Is Philip J. Johnson Influential?

Philip J. Johnson's Published Works

Published Works

What Schools Are Affiliated With Philip J. Johnson?

Philip J. Johnson's AcademicInfluence.com Rankings